Entry deadline: 18 June 2021 Thursday, 2 December Royal Lancaster London scripawards.com
For entry and general enquiries please contact: Jo Kirkpatrick | jo.kirkpatrick@informa.com
Entries are now open for the 17th Annual Scrip Awards. Since they began, the Scrip Awards has sought to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising.
This is your chance to gain recognition for and showcase your hard work at an event full of industry professionals.
Credibility sells – Winning this prestigious accolade is marketing that money can’t buy.
Master your sector – Our Awards cover activities across that the pharmaceutical, biotech and other allied industries, from start ups to big pharma.
You don’t have to be big – You just have to be the best!
The Scrip Awards are FREE to enter! You have done the hard work, now all you need to do is convince the independent panel of experts judging this year’s Awards.
Entry deadline: 18 June 2021
The Scrip Awards is open to any research-based pharmaceutical or biotech company operating anywhere around the world, as well as to some third-party / partner companies that supply services to the pharmaceutical industry.
Select the relevant category/ies for your business and review the entry criteria at scripawards.com
Complete the online entry form answering all questions, explaining why you or your company should be considered a winner this year. Please refer to the category criteria to guide your entry form at https://www.eventsforce.net/scrip-awards-21
Submit your entry by 18 June 2021 online via https://www.eventsforce.net/scrip-awards-21 (you will receive an automated submission receipt)
For entry and general enquiries please contact: Jo Kirkpatrick | Tel: +44 (0) 7917 555 986 | Email: jo.kirkpatrick@informa.com
The Final Entry Deadline is 18 June 2021
All entries must be written in English.
All entries must be accompanied by a 250-word synopsis of the entry which may be used in Awards publicity material (this is in addition to the entry)
All entries must be submitted via our online entry system
All entries must be based on activities undertaken between 1 June 2020 and 31 May 2021
Answer each question under a separate heading, as specified in the category criteria
Do not provide any supporting documentation – all information should be included within your entry
Plan ahead to ensure you submit the entry ahead of the entry deadline, so that, should it be incomplete, there will still be time to correct and resubmit it before the closing date
All entries will be treated as confidential, but Scrip reserves the right to publish positive extracts from winning entries
All companies shortlisted as finalists will be notified directly by Scrip in September
The judging panel reserve the right to move an entry into a different category if they feel it is better suited in this category
Companies may enter more than one category, provided that each entry has been specifically written to address the relevant criteria and is accompanied by a separate 250-word synopsis.
For this special Award, candidates must be nominated by a third party. The nomination should outline in no more than 1,500 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.
The name of the nominee
The job title of the nominee (if applicable)
The company name (if applicable)
Your contact details
The contact details of the nominee
A précis of up to 1,500 words explaining why you think your nominee is worthy of receiving the Lifetime Achievement Award
China Biopharma Leadership Award
Community Partnership of the Year
MSD’s Innovation Award
Clinical Advance of the Year (sponsored by Parexel)
Financing Deal of the Year
Licensing Deal of the Year
Best Partnership Alliance
Business Development Team of the Year
Executive of the Year
Best Contract Research Organization – Full-Service Providers (sponsored by Bioclinica)
Best Contract Research Organization – Specialist Providers
WuXi AppTec's Biotech Company of the Year
Best New Drug Award
Pharma Company of the Year (sponsored by IQVIA)
Scrip’s Lifetime Achievement Award
Scrip’s China Biopharma Leadership Award reflects the rapid maturing of China’s biopharma sector, thanks to the development of homegrown biopharma companies, CDMOs and increasing investment in the market from global multinational biopharma companies.
The category seeks to reward firms that have shown leadership in developing China’s biopharma sector through significant commercial and R&D activity, and by helping patients access new treatments through new launches and successful negotiations with China’s healthcare payers and clinical leaders.
This Award is open to any research-based pharmaceutical company either headquartered in China or with a significant presence in the market through its own investment or via a major partnership.
The judges will be looking for excellent performance across business activities achieved between June 1, 2020 and May 31, 2021. This could include a range of leadership activities, from launching new products, or signing a transformative new commercial deal or working with Chinese authorities on innovation in healthcare and patient access.
To enter this category, please answer the following: Please give the name of the entering company and country where it is headquartered. What has been this company’s most significant achievement during the year?
Give details of what this company has achieved in terms of:
Growth in sales and profits
Signing important new deals
Introducing new products onto the market
Producing a promising new drug pipeline
Operational improvements, particularly after restructuring, or changing the focus of the business
Collaboration with government and regional authorities on patient access and healthcare modernization
This Scrip Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organization.
The judges will be looking for effective partnership activity that took place between June 1, 2020 and May 31, 2021 to the benefit of humankind. Types of partnerships could include, for example, patient and carer support programs, educational programs or disease awareness campaigns or even a social media campaign that went viral.
To enter this category, please answer the following:
Please give the name of the entering company and the name of the partnership
Please outline the nature of the partnership being entered
What were the aims of the partnership?
What were the benefits of the partnership and how were they measured?
What lessons were learned from the partnership and how might it be improved in future?
This category will acknowledge and celebrate the outstanding scientific or technological breakthrough that the judging panel believes has the potential to be transformative in the discovery or development of new medicines.
The award is open to any person, group or company that has achieved a genuinely ground-breaking advance during the qualifying period of 1 June 2020 to 31 May 2021. We welcome entries that are active in the life sciences ecosystem – from early-stage research through to clinical proof-of-concept developments.
Achievements we wish to recognize include: insights that advance our understanding of disease biology; new therapeutic targets or approaches; elucidation of a novel mechanism of action; clinical proof of concept of a novel mechanism or novel target; and techniques and technology platforms that enhance the medical benefits of new or existing medicines.
Entries will be judged on the answers to a number of key questions:
What is the scientific, technological or medical challenge they are targeting?
What is the solution to the challenge?
What proof of principle or concept have been achieved?
How will the entry impact either the discovery or development innovative therapeutic approaches?
How novel is the innovation?
This Scrip Award seeks to recognize success in a clinical trial of a new drug product that is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.
Unlike the Best New Drug Award, the product involved need not yet be approved, but as with that award the judges will be looking for innovation, clear proof of benefit and potential commercial reward.
To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between June 1, 2020 and May 31, 2021.
Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.
To enter this category, please answer the following questions:
Please give full details of the study, i.e., its name (protocol ID, trial identifier), Phase, disease type and patients segment studied, sponsors, and the primary drug tested.
Please summarize the major findings of the study, including all primary/co-primary and main secondary endpoints, and safety endpoints.
How does the drug work in the setting tested?
How do these findings represent a potential leap forward in therapy, or fulfil an unmet medical need?
What could be the potential market size of this breakthrough?
This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech companies. The investment can come in a variety of guises from grants and public-private partnership deals to venture fundraising and public offerings, but should be earmarked for use in drug discovery and/or development.
In making their decision, the judges will scrutinize entrants on their fundraising strategy, amount raised, the structure of the deal, and on how the money will be used. This Award is open only to companies actually raising the funds (i.e., not bankers or agents). To be eligible, all financing must have been announced between June 1, 2020 and May 31, 2021.
Please outline the form of the financing, how much money was raised (including how this compares with the company’s capital base), and how close was this to meeting your fundraising objectives?
Please explain how this source of financing was best suited to your purposes.
Please describe how this fundraising was particularly creative. Has this set a precedent that has since been repeated?
Did the funding succeed in other ways, such as bringing on board a new kind of investor?
How will the money be used?
Please give evidence of early value creation from the deal.
Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing. (NB It does not include more involved partnerships between companies to explore particular therapeutic strategies (see criteria for the Best Partnership Alliance Award).)
In choosing the winner of Scrip’s Licensing Deal of the Year, the judges will look at all aspects of the submitted transactions, from their monetary and strategic value, to the benefits they give to both sides. To qualify, licensing deals must have been closed between June 1, 2020 and May 31, 2021.
Please outline the structure of the deal, giving the names of the parties involved, the drug candidate(s) concerned, and what rights it covers.
What is the monetary value of the deal in up-front and milestone payments?
What is the geographic spread of the deal? Does it allow any party to enter new markets?
What is the strategic value of the licensed product to the licensee’s business?
Please explain how the licensed product was the best possible candidate to complement the rest of the licensee’s pipeline or particular disease franchise.
IMPORTANT NOTE: Would your entry fit better in the Best Partnership Alliance category? Please consider before you enter.
Scrip’s Best Partnership Alliance Award recognizes the importance of pharmaceutical and/or biotech companies working together to develop new medicines. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in developing new drugs from the earliest stages.
The judges will be focusing on deals that require strong strategic input from both partners, involving business development, joint marketing/promotion or joint R&D. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure.
Partnerships must have been announced, or have achieved a significant milestone, between June 1, 2020 and May 31, 2021 and entrants should be able to show some sustained benefits from the deal. NB: Deals between majority or wholly owned subsidiaries and their parent companies are not eligible for this Award.
Please give the name of company/organizations involved.
Please outline the structure of the partnership, detailing the parties involved, what it covers and the responsibilities on both sides.
Does its structure represent an innovative business model, and if so how? How does it demonstrate that either party was the "partner of choice"?
Please summarize the strategic potential of the deal, and if applicable the milestone reached.
Please explain how the deal is mutually beneficial to both parties.
What aspect of the deal makes it unique or particularly special?
How does the collaboration hope to meet any unmet medical need?
IMPORTANT NOTE Would your deal fit better into the Licensing Deal of the Year category? Please check before you enter.
Scrip’s Business Development Team of the Year will honor the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.
This Award will go to a team that is truly much more than the sum of its parts. The judges will be looking for strong performance across a number of criteria, such as achievement of short and long-term goals, and good communication of a shared vision.
Please give details of the company(ies), the particular team being entered and its core function.
Please describe the team’s goals and vision, and how these are communicated.
What was the greatest achievement of the team during the year between June 1, 2020 and May 31, 2021?
Please describe how all parts of the team were fully aligned to achieve this, including how supporting functions, such as HR, finance and IT, were integrated into the team.
Rate the team, giving justification, according to the following criteria:
Achieving short-term and long-term goals
Managing resources
Providing a platform for professional development and teamwork
How does the team embody a management model that others should follow?
Scrip’s Executive of the Year is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies. This year’s winner will be the executive who has exhibited exemplary leadership throughout 12 months from June 1, 2020 to May 31, 2021.
This could range from leading an emerging company to an established place within the industry, to turning around the fortunes of a failing company or unit, or leading a firm successfully through the turbulence of a merger or acquisition. Also important to the judges will be the executive’s career achievements, influence within the industry and leadership qualities.
To be eligible for this year’s Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.
Please give the name, company and position of the entrant, and the date of taking up this post.
What have been the entrant’s greatest achievements during the qualifying year? What has been the direct consequence of these on company performance?
How have these achievements strengthened the candidate’s influence within the industry? Please give examples.
What are the entrant’s greatest strengths as a leader? Please show how these have had a bearing on their achievements this year.
What specific previous accomplishments did the entrant have that made them perfectly fitted to achieving this success? For example, previous scientific or management experience.
The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.
This Award is split into two categories to separate the full-service providers from those smaller CROs that provide specialist services to their clients. Today, the role of the CRO has gone beyond the traditional model of service-level agreements to offer bespoke clinical trial strategies and CROs are increasingly engaged in risk-sharing partnerships or acting as a single-source developer while also remaining committed to core strengths.
This Award for those companies who provide the full range of services to their clients will be judged on the quality of services and relationships they have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal. To qualify, candidates must draw on their achievements in the year between June 1, 2020 and May 31, 2021.
What particular capabilities and strengths does the CRO offer?
How has this firm delivered results that exceed sponsor expectations?
What innovations in patient recruitment strategy has the CRO brought to its partner?
How has it improved its performance, for example, in its quality of data, timelines and transparency?
What steps is the company taking towards streamlining data collection and reporting?
This Award is split into two categories to separate the full-service providers from those smaller CROs that provide specialists services to their clients.
This Award for those companies who provide specialist services to their clients will be judged on the quality of services and relationships they have built with their clients. To qualify, candidates must draw on their achievements in the year between June 1, 2020 and May 31, 2021.
What innovations has the CRO brought to its partner?
The biotech industry’s entrepreneurial spirit and cutting-edge science are vital to the lifesciences industry and the research and development of medicines in the past few decades. This award honors outstanding achievement by biotech companies over the qualifying 12 months.
The winner of the Biotech Company of the Year Award will be the biotech firm that has achieved the most in the 12 months between June 1, 2020 and May 31, 2021. This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.
Name of entering company.
What has been the company’s most significant achievement during the year?
Give details of what the firm has accomplished over the year in terms of:
Bringing new products closer to their first markets
Raising funds
Signing significant licensing or partnership deals
Showing strong management not afraid of making hard decisions
Using proprietary science or technologies to address an unmet medical need
Successfully transforming the business from an early stage to a more mature company
The Best New Drug Award recognizes excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.
In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.
All recently launched new active substances, including small-molecules, biologicals or vaccines, are eligible to enter as long as they were first licensed in any market between June 1, 2020 and May 31, 2021. Generic and biosimilar products are not eligible for this award.
Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.
Please give the trade and generic name of the entrant, the therapeutic indication for which it is being considered, and the company(ies) involved in its development (if more than one company, please detail the relationship between the parties).
What was the date and market of the candidate’s first approval and launch?
Please explain the mechanism of action of the candidate. How does this represent a step forward in treatment in this therapeutic area?
Please outline the evidence for the product’s clinical activity. How does its activity translate into a meaningful therapeutic benefit for patients, and how is this benefit over and above that provided by other treatments in this area?
How does the entrant address an unmet medical need?
What is the potential market size of the candidate?
Scrip’s Pharma Company of the Year honors outstanding achievement by pharmaceutical companies over the qualifying 12 months, June 1, 2020 and May 31, 2021. This special award is chosen by Scrip's senior editorial team, based on a variety of key metrics:
Financial performance in 2020 compared with the previous year.
Strategic advances, looking at its most significant achievements over the year.
Progress in the emerging markets.
New product launches including line-extensions and formulations.
Advances in the drug pipeline, including major clinical trial reports.
The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career.
This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry. We welcome nominees for consideration for this award but the decision lies with Scrip's senior editorial team. The winner may be retired or semi-retired but will still be active in the industry in some capacity.
Any nomination should outline in no more than 1,500 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.
All nominations must include:
The name of the nominee.
The job title of the nominee (if applicable).
The company name (if applicable).
Your contact details.
The contact details of the nominee.
A précis of up to 1,500 words of why you think your nominee is worthy of receiving the Lifetime Achievement Award
The Scrip Awards will culminate in a gala black-tie dinner and Awards ceremony on Thursday 2 December at The Royal Lancaster London.
Please note we plan to host a live event, and will be following all Government guidelines to ensure we can do this safely, should we not be able to hold a physical event we will post updates on our website.
For security purposes, attendance at the event is by ticket only and guests are required to provide some personal details beforehand. All shortlisted companies and individuals are advised to attend.
To discuss table bookings and event sponsorship please contact:
Christopher Keeling Mobile: +44 (0) 7917 647 859 Email: christopher.keeling@informa.com Or visit www.scripawards.com
The Scrip Awards prides itself on its Judging Panel, comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility. The judges separately consider entries from those categories that are relevant to their particular areas of specialist knowledge, expertise and experience, ensuring a considered response to every individual submission.
Each category is reviewed by at least three judges. The judges mark each entry against the published criteria for its category, and the scores are marked out of ten for each category answer. These are then collated by the Scrip Awards team to determine which entries are included in the shortlist, and the ultimate winner.
The chair of the Judging Panel reserves the right to cast any deciding vote, should the need arise. The judges’ decision is final and neither the organisers nor the Judging Panel will enter into any correspondence about the results.
Judging will take place throughout the summer, and the shortlist will be announced in September. Details of the winners are strictly embargoed until the night but further details of all of the shortlisted entries will be published in Scrip in the weeks leading up to the ceremony on Thursday 2 December at The Royal Lancaster London.
Informa, organizer of the Scrip Awards, recognizes and respects the sensitive nature of the information submitted in the entries. We ensure that this recognition is shared by our Judging Panel and therefore require each judge to sign a confidentiality agreement before they are appointed. Entries are not disclosed or discussed outside the judging process. The Judging Panel for each Award is selected to avoid any conflict of interest. Once an entry is shortlisted, extracts from the entry summary only will be sourced for inclusion in the Awards ceremony and any subsequent editorial coverage. Please ensure your entry summary contains no confidential or sensitive information.
Q. How do I enter? A. It’s very simple. Ensure you have read the entry guidelines and category criteria. Decide which category/categories you wish to enter, and create your on-line account at https://www.eventsforce.net/scrip-awards-21. Once you are ready click ‘Enter Now’, follow the onscreen instructions, saving your entry as you go. Ensure you submit your entry on your account page, by ticking the box next to the entry you wish to submit and click the ‘Submit’ button.
Q. How much does it cost to enter? A. Entering the Scrip Awards is FREE of charge.
Q. When is the entry deadline? A. Entries are being accepted until 18 June 2020.
Q. I am not sure which category our entry would fit into? A. If you are not sure which category your entry fits into, please contact Jo Kirkpatrick at jo.kirkpatrick@informa.com for further assistance.
Q. Can I enter the same submission into more than one category? A. We encourage entries in more than one category per individual or company, where appropriate; please ensure to review the category criteria and tailor your entry accordingly.
Q. I am a sponsor of the Awards am I still able to enter? A. Yes you can enter the Awards. And we would encourage this, however you are unable to enter the category you are sponsoring. But don’t worry there are plenty of other categories.
Q. How will I know whether my submission has been received? A. All submissions will be acknowledged by an automated email once you have submitted your entry. Our Awards team will also get in touch with you again shortly before the entry deadline. If you have any concerns, please contact Jo Kirkpatrick at jo.kirkpatrick@informa.com
Q. How will I know if my submission has been successful? A. Following the judging all companies and individuals will be notified by email. Finalists will be announced on our website, www.scripawards.com. If you are successful, you will also receive an email from us on what happens next.
Q. What do I get if I win? A. The Scrip Awards are highly regarded within the industry and winning an Award marks you out as a leader in your field. In addition to your trophy and a certificate of recognition you will receive a winner’s pack with additional details on publicizing your success.
Q. How can I ensure I’m at the ceremony for the networking? A. It’s essential to book your place at the event. Please contact Christopher Keeling at Tel: +44 (0) 7917 647 859 or Email: christopher.keeling@informa.com for information.
Q. Are there other ways I can get involved in the Awards? A. Yes, there are many sponsorship opportunities available. Please contact Christopher Keeling at Tel: +44 (0) 7917 647 859 or Email: christopher.keeling@informa.com for information.
Q: Will the Awards ceremony be held as a physical event? A: We will be following Government guidance for the safety of everyone attending, details of which will be shared with you nearer the event. Should we not be able to hold a physical event, we will post updates on our website and any attendees will be notified.
For Entry and General Enquiries: Jo Kirkpatrick Tel: +44 (0) 7917 555 986 Email: jo.kirkpatrick@informa.com
For Sponsorship and Table Booking Enquiries: Christopher Keeling Tel: +44 (0) 7917 647 859 Email: christopher.keeling@informa.com